Arsenal Biosciences Stock

arsenalbio.comBioTechFounded: 2019Funding to Date: $85MM

ArsenalBio is a biotechnology company looking to develop efficacious and safe cellular therapies for patients with chronic diseases.

Register for Details

For more details on financing and valuation for Arsenal Biosciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Arsenal Biosciences.

Register Today

Team

Management Team

Kenneth Drazan MD
Co-Founder, Director, Chief Executive Officer, President and Board Member
Tarjei Mikkelsen
Chief Technology Officer
Jane Grogan
Chief Scientific Officer

Board Members

Alexander Marson Ph.D
Beth Seidenberg MD
Westlake Village BioPartners
Brook Byers Ph.D
Kleiner Perkins
Sean Parker
Parker Institute for Cancer Immunotherapy

Other companies like Arsenal Biosciences in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$3.1B
Sector
 
 
Sector
Last Round Est. Valuation
$5.81B
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$1.61B
Sector
Last Round Est. Valuation
$1.77B

News

The story behind ArsenalBio begins with Sean Parker’s Institute for Cancer Immunotherapy. Founded in 2016, the Institute has been instrumental in providing a space for the top researchers into cancer across different fields to collaborate and communicate on the latest breakthroughs in setting…
ArsenalBio, a South San Francisco, Calif.-based programmable cell therapy company, raised $85m in Series A financing round